A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm.

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

PSMA PET-CT is a diagnosit tool helping save men's lives with prostate cancer that has spread beyond the prostate gland Dr. David Samadi says that men with aggressive prostate cancer or a very high ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

A world-first trial of Australian men has confirmed a specialised scan can accurately “light up” prostate cancer, saving unnecessary and painful biopsies and stress of over-diagnosis.

Daniel Oguna, a PET CT technologist prepares a patient for a scan procedure at Aga Khan University Hospital, Nairobi. [Photo: Standard] The latest and most advanced scan for evaluation of patients ...

Approximately 20% to 40% of men who have surgery for localized prostate cancer will see the cancer return within 10 years, often first detected by a rising PSA blood test. When this happens, doctors ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.